Bausch Health Companies Inc BHC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Bausch Health Announces Availability of Solta Medical's Fraxel FTX® in Australia
-
Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners
-
Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners
-
Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board
-
BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE
-
Bausch Health to Announce Second Quarter 2026 Results on July 29, 2026
-
Michael Goettler Resigns from Bausch Health's Board of Directors
Trading Information
- Previous Close Price
- $6.76
- Day Range
- $6.52–6.72
- 52-Week Range
- $4.33–8.00
- Bid/Ask
- $6.52 / $6.80
- Shares Outstanding
- 373.99M
- Market Cap
- $2.45B
- Volume/Avg
- 2M / 4M
Key Statistics
- Price/Earnings (Normalized)
- 1.54
- Price/Sales
- 0.23
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 20,300
- Website
- https://www.bauschhealth.com
Valuation
|
Metric
|
BHC
|
|---|---|
Price/Earnings (Normalized) | 1.54 |
Price/Book Value | — |
Price/Sales | 0.23 |
Price/Cash Flow | 1.19 |
Price/Earnings
BHC
Financial Strength
|
Metric
|
BHC
|
|---|---|
Quick Ratio | 0.90 |
Current Ratio | 1.44 |
Interest Coverage | 0.52 |
Quick Ratio
BHC
Profitability
|
Metric
|
BHC
|
|---|---|
Return on Assets (Normalized) | 6.23% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | 14.13% |
Return on Assets
BHC
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|Crh>y#W | LOCK|zzzGl | $69B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|j>qD!YPS | LOCK|#&LMF | $42B | |||
| Haleon PLC ADR
HLN
| LOCK|?%nbF#Y | LOCK|## | $42B | |||
| Zoetis Inc Class A
ZTS
| LOCK|X&?v>%N | LOCK|D% | $31B | |||
| Viatris Inc
VTRS
| LOCK|$@$p$G@ | LOCK|BWF | $19B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|$P | LOCK|n%r | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|#!g<?# | LOCK|YZ | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|BRV@Fm | LOCK|nC@ | $6B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|m<!kxd | LOCK|n<h## | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|$k@trl | LOCK|$b | $2B |
United States